rs7234029 — PTPN2

PTPN2 — The Phosphatase That Keeps Your T-Cells in Check

Inside every T-cell, a molecular brake pedal controls how aggressively the cell responds to immune activation signals. That brake is TC-PTP (T-cell protein tyrosine phosphatase)¹¹ TC-PTP (T-cell protein tyrosine phosphatase)
A non-receptor protein tyrosine phosphatase encoded by PTPN2 that dephosphorylates and inactivates JAK1, JAK3, STAT1, STAT3, and STAT5 — the core signaling proteins that drive T-cell proliferation and cytokine production. When TC-PTP functions at full strength, it restrains T-cell activation to a level proportional to the actual threat. When TC-PTP expression is reduced, that restraint weakens — the immune system activates more readily, sustains responses longer, and is more prone to misdirecting attacks against self-tissue. rs7234029 is an intronic variant in PTPN2 whose G allele is consistently associated with reduced TC-PTP expression and, consequently, with increased susceptibility to a cluster of autoimmune and inflammatory conditions spanning the gut, joints, and endocrine system.

The Mechanism

The G allele of rs7234029 sits within an intron of PTPN2 and is associated with reduced expression of the TC-PTP protein, though the precise regulatory element disrupted has not been fully characterized. At the functional level, the consequence is reduced JAK/STAT pathway²² JAK/STAT pathway
JAK kinases (JAK1, JAK3) and STAT transcription factors (STAT1, STAT3, STAT5) are the primary intracellular relay for cytokine signals including IL-2, IL-6, IFN-γ, and IL-15 — signals that drive T-cell activation, proliferation, and differentiation dephosphorylation. With less TC-PTP activity, JAK1 and JAK3 remain phosphorylated (active) longer after cytokine stimulation, STAT proteins accumulate in the nucleus for extended periods, and T-cells produce larger amounts of pro-inflammatory cytokines — particularly TNF-α, IFN-γ, and IL-17. In the intestinal epithelium, PTPN2 loss additionally disrupts the tight junction network that maintains the gut barrier, promoting the bacterial translocation and immune amplification that characterizes IBD. The Spalinger et al. macrophage study³³ Spalinger et al. macrophage study
Gastroenterology 2020; conditional knockout model of PTPN2 deletion in macrophages and intestinal epithelial cells demonstrated that PTPN2- deficient macrophages shift to a pro-inflammatory M1-like phenotype with elevated IL-6 production and STAT3 hyperphosphorylation — mirroring the inflammatory profile seen in IBD patients who carry the disease-associated PTPN2 variant.

The Evidence

The strongest body of evidence for rs7234029 comes from inflammatory bowel disease and autoimmune arthritis. A meta-analysis of 17 studies⁴⁴ meta-analysis of 17 studies
Zhang JX et al., Inflamm Res 2014; 18,308 cases and 20,406 controls found that G allele carriers had a 36% increased risk of Crohn's disease (OR=1.36, 95% CI 1.16–1.59, I²=0%), a homogeneous result across studies suggesting robust replication. A German case-control study⁵⁵ German case-control study
Glas J et al., PLoS One 2012; 905 CD patients, 318 UC patients, 908 controls found p=1.30×10⁻³ (OR 1.35) for rs7234029 and Crohn's disease specifically, and made the clinically relevant observation that the variant was associated with the stricturing disease phenotype (B2) in CD patients (p=6.62×10⁻³) — the most aggressive intestinal phenotype characterized by fibrostenotic lesions.

In the joints, the evidence is equally robust. A multi-disease GWAS of shared autoimmunity loci Thompson SD et al., Arthritis Rheum 2010; 809 JIA cases, 3,535 controls with replication in 1,015 additional JIA cases⁶⁶ Thompson SD et al., Arthritis Rheum 2010; 809 JIA cases, 3,535 controls with replication in 1,015 additional JIA cases found rs7234029 OR=1.35, P=1.86×10⁻¹⁰, confirming PTPN2 as one of seven validated shared autoimmune loci spanning RA, T1D, Crohn's disease, and multiple sclerosis. An independent European RA GWAS Cobb JE et al., PLoS One 2013; 4,286 RA patients, 5,642 controls⁷⁷ Cobb JE et al., PLoS One 2013; 4,286 RA patients, 5,642 controls found genome-wide significant evidence for rs7234029 at P=4.4×10⁻⁹, describing PTPN2 as "a pan-autoimmune susceptibility gene" in Caucasian populations.

The variant also has pharmacogenomic relevance. A Crohn's disease treatment study Hoffmann P et al., Genes Basel 2021; 379 CD patients⁸⁸ Hoffmann P et al., Genes Basel 2021; 379 CD patients found that rs7234029 G allele carriers had substantially higher non-response rates to anti-IL-12/23 therapy (89.9% vs 67.6%, p=0.005). In rheumatoid arthritis, a prospective cohort study Conigliaro P et al., PLoS One 2017; 171 RA patients⁹⁹ Conigliaro P et al., PLoS One 2017; 171 RA patients found the PTPN2 variant associated with reduced EULAR response to adalimumab at 6 months — a finding consistent with the biology, since adalimumab blocks TNF-α, and PTPN2-deficient cells overproduce TNF-α through JAK/STAT hyperactivation.

Practical Actions

For G allele carriers, the primary implication is a modestly elevated risk for Crohn's disease, rheumatoid arthritis, and juvenile idiopathic arthritis. These conditions share early warning signs — unexplained joint pain, changes in bowel habits, fatigue — that are worth taking seriously and evaluating promptly. Early diagnosis and treatment initiation before significant intestinal or joint damage has occurred meaningfully improves outcomes in all three conditions. For individuals who already carry a diagnosis of CD or RA, the G allele's association with reduced response to anti-IL-12/23 therapy (in CD) and anti-TNF therapy (in RA) is emerging evidence — not yet sufficient for clinical decision-making alone — but worth discussing with a specialist when treatment options are being considered.

Interactions

rs7234029 is one of three commonly studied PTPN2 variants in IBD and autoimmune disease. The other two — rs1893217 (intronic, OR=1.45 for CD in meta-analysis) and rs2542151 (intronic, OR=1.22 for CD) — tag different aspects of PTPN2 regulation and are not in strong LD with rs7234029. Carrying the risk allele at multiple PTPN2 variants compounds the risk beyond any single variant alone. Additionally, PTPN2 operates in the same pathway as STAT3 and JAK1/JAK3 — the targets of tofacitinib and other JAK inhibitors approved for IBD and RA. This makes PTPN2 variants biologically relevant to JAK inhibitor pharmacogenomics, though clinical guidelines have not yet incorporated PTPN2 genotyping for JAK inhibitor selection.